AstraZeneca

Selected news for the company - AstraZeneca, collected since 4/2019. Recent stories appear in The Wall Street Journal and FierceBiotech. This company shares news with COVID-19, COVID-19 Vaccine, Coronavirus, Pfizer, Coronavirus Vaccine and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/27/2021 A clarification/correction on Jamaica's vaccination numbers; and new COVID restrictions start tomorrow Wordpress.com ... of vaccines administered, NOT the total number of people vaccinated.The Ministry reported today that as of Sunday, July 25 their numbers are: 178,444 first doses have been administered, and 123,848 second doses of AstraZeneca . This adds up to a total of 302,856 doses administered. As you can see, there is still a bit of a gap between the first and second dose numbers, and those who are now due ...
7/27/2021 Medical Anesthesia Agent Market 2021 Highlights Recent Trends, Market Growth, Business Opportunities till 2027 themarketpublicist.com ... to consolidate the information in the report.. They have also used the same data to generate the current business scenario. Top Leading Companies of Global Medical Anesthesia Agent Market are Pfizer, Baxter International, Merck, AstraZeneca , B-Braun, Hengrui Medicine, Piramal Critical Care, Lunan Pharmaceutical Group, Fresenius AG, Jiangsu Nhwa Pharmaceutical Co., Ltd., Humanwell Healthcare, Xi’an Libang Enterprises, Maruishi, Endo Pharmaceuti and others. Get Free Sample Copy of this Report ...
7/26/2021 Global Lung Cancer Therapeutics Market | Are you willing to … flickr.com ... request-a-sample/?dbmr=g... Some of the prominent players operating in this market are Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca , Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, AMGEN INC., Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb ...
7/26/2021 The Latest Google Censorship Due to Their Vaccine Investment bwcentral.org Story at-a-glance - YouTube’s parent company, Google, is directly invested in the AstraZeneca /Oxford COVID “vaccine.” This is why YouTube censors anything that threatens the rollout and future profits of COVID-19 gene modification therapies - Silicon Valley has been pushing to transform the health care system into a system based on telemedicine and personalized care through the use of artificial intelligence (AI). Google is heavily involved in ...
7/26/2021 New South Wales could give out 350,000 vaccines a day if supply wasn't an issue mogaznews.com ... vaccination hub wait in line) Insurance Loans Mortgage Attorney Credit Lawyer 'Ultimately, if we had more vaccine, we could do more,' Dr Chant told reporters, adding that she urged the public to consider the AstraZeneca option which is in plentiful supply. Dr Chant also said the lack of Pfizer supply combined with hesitancy over AstraZeneca because of a very rare blood clot side effect, was contributing to older Australians - those ...
7/26/2021 New South Wales could give out 350,000 vaccines a day if supply wasn’t an issue internewscast.com ... residents at the Olympic Park vaccination hub wait in line) ‘Ultimately, if we had more vaccine, we could do more,’ Dr Chant told reporters, adding that she urged the public to consider the AstraZeneca option which is in plentiful supply. Dr Chant also said the lack of Pfizer supply combined with hesitancy over AstraZeneca because of a very rare blood clot side effect, was contributing to older Australians – ...
7/26/2021 New South Wales could hand out 350,000 vaccines a day if delivery wasn't an issue - Ali2day-News Of America ali2day.com ... problems (Photo: Olympic Park Vaccination Center residents waiting in line) “Ultimately, if we had more vaccine, we could do more,” Dr Chant told reporters, adding that she urged the public to consider the AstraZeneca option, which is abundant. dr. Chant also said the lack of Pfizer stock combined with hesitation about AstraZeneca due to a very rare side effect of blood clots helped older Australians – those most at ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children Yahoo News Reuters) -AstraZeneca said on Monday the European Medicines Agency (EMA) recommended approving a medicine from its U.S.-based Alexion unit for treating a rare, deadly blood disorder in children and adolescents aged up to 18 years.The drugmaker recently completed its $39-billion acquisition of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children wdez.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children - Up News Info upnewsinfo.com Article content AstraZeneca said on Monday the European Medicines Agency (EMA) recommended approving a medicine from its U.S.-based Alexion unit for treating a rare, deadly blood disorder in children and adolescents aged up to 18 years.The drugmaker recently completed its $39-billion acquisition of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children 933thedrive.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children - Netscape News netscape.com 07/26/2021 6:45 (Reuters) -AstraZeneca said on Monday the European Medicines Agency (EMA) recommended approving a medicine from its U.S.-based Alexion unit for treating a rare, deadly blood disorder in children and adolescents aged up to 18 years.The drugmaker recently completed its $39-billion acquisition of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children kelofm.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children go955.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children 943jackfm.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children b93radio.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children cruisin929.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children kfgo.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children froggyweb.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...
7/26/2021 EU regulator backs AstraZeneca drug for rare blood disorder in children hi99.com ... of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. AstraZeneca said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows a U.S. approval in June. The EMA endorsement is ...